AGLE Aeglea BioTherapeutics Inc.

6.85
+0.07  (+1%)
Previous Close 6.78
Open 6.79
Price To Book 1.7
Market Cap 197,610,876
Shares 28,848,303
Volume 2,147
Short Ratio
Av. Daily Volume 158,593

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021. Phase 1/2 further data due September 2019.
Pegzilarginase (AEB1102)
Arginase I deficiency
Phase 1 dose escalation data presented at AACR April 15, 2018.
AEB1102
Solid tumors
Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102)
Solid tumors
Phase 1/2 top-line data due 1H 2020.
Pegzilarginase (AEB1102) + KEYTRUDA
Small cell lung cancer (SCLC)

Latest News

  1. Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares
  2. Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)
  3. Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
  4. Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
  5. These 3 Biotech Stocks Are Attracting Insider Buying
  6. Aeglea: 1Q Earnings Snapshot
  7. Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
  8. Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
  9. Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
  10. Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
  11. Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
  12. Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
  13. Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
  14. Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript
  15. Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
  16. The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
  17. Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
  18. Aeglea aims to raise $60M for treating rare diseases
  19. Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering